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Abstract: MYC-translocated T-lineage acute lymphoblastic leukemia (T-ALL) is a rare subgroup
of T-ALL associated with CDKN2A/B deletions, PTEN inactivation, and absence of NOTCH1 or
FBXW7 mutations. This subtype of T-ALL has been associated with induction failure and aggressive
disease. Identification of drug targets and mechanistic insights for this disease are still limited. Here,
we established a human NOTCH1-independent MYC-translocated T-ALL cell line that maintains the
genetic and phenotypic characteristics of the parental leukemic clone at diagnosis. The University
of Padua T-cell acute lymphoblastic leukemia 13 (UP-ALL13) cell line has all the main features
of the above described MYC-translocated T-ALL. Interestingly, UP-ALL13 was found to harbor
a heterozygous R882H DNMT3A mutation typically found in myeloid leukemia. Chromatin
immunoprecipitation coupled with high-throughput sequencing for histone H3 lysine 27 (H3K27)
acetylation revealed numerous putative super-enhancers near key transcription factors, including
MYC, MYB, and LEF1. Marked cytotoxicity was found following bromodomain-containing protein
4 (BRD4) inhibition with AZD5153, suggesting a strict dependency of this particular subtype of
T-ALL on the activity of super-enhancers. Altogether, this cell line may be a useful model system for
dissecting the signaling pathways implicated in NOTCH1-independent T-ALL and for the screening
of targeted anti-leukemia agents specific for this T-ALL subgroup.
Keywords: MYC-translocated leukemia; T-lineage acute lymphoblastic leukemia; NOTCH1-independent;
super-enhancers; BRD4 inhibition; targeted therapy
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1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) represents approximately 15% of pediatric and
25% of adult ALL cases and is characterized by a high prevalence of activating mutations in
the NOTCH1 gene [1]. T-ALL is a fairly heterogeneous disease which includes several major
subgroups associated with specific chromosomal rearrangements and is defined by characteristic
gene expression signatures such as TAL-LMO, TLX1/TLX3, or HOX-like [2–4]. Interestingly,
the presence of NOTCH1 mutations appear to be associated with a favorable therapeutic response,
while NOTCH1-independent T-ALL cases have a less favorable prognosis [5]. However, conflicting
results have been reported on the prognostic impact of NOTCH1 activating mutations, possibly
due to differences in therapy intensification [6]. An understanding of the genetic/molecular
pathways implicated in and sustaining NOTCH1-independent T-ALLs is required to identify novel
therapies. An emerging group of NOTCH1-independent TAL/LMO-positive leukemias harboring
MYC translocations (constituting around 1–6% of adult and childhood T-ALL cases) has been
recently described [7,8]. This rare subgroup frequently presents with aggressive disease and poor
response to standard therapy. Currently, a limited number of cell lines are available that are
NOTCH1 or NOTCH3 wild-type (wt), such as MOLT-16 [9]. Interestingly, MOLT-16 [10] is also
characterized by t(8:14)(q24;q11)/TCRAD-MYC translocation, SIL-TAL1 and LMO2 translocations
as primary alterations, and CDKN2A/B deletions and PTEN deletions or mutations as additional
abnormalities. The genetic profile of this cell line and leukemia cases containing t(8:14)(q24;q11)
leading to MYC overexpression with NOTCH1wt/FBXW7wt/PTEN mutation or deletion resembles
that of a recently described Notch1-independent mouse leukemia model arising following conditional
Pten deletion [11]. This profile is also similar to a NOTCH1-independent/MYC-mediated T-ALL
subset, where concurrent PTEN down-regulation/inactivation contributes to MYC over-expression [12].
Given the recent limitations reported with established cell lines, including multiple transformations
and derivations, misidentification, and cross-contamination with other cell line(s) [13], it would
be desirable to test and develop anti-cancer drugs using well-characterized cell lines that preserve
patterns of responsiveness to micro-environmental stimuli and maintain the integrity of the signaling
pathways engaged by these stimuli. In contrast to primary leukemia cells, which undergo spontaneous
apoptosis in vitro and whose viability can be rescued by cytokine cocktails [14,15] or stromal cells [16]
(suggesting that normally in vivo micro-environmental cues are important for sustaining their growth
and survival), available T-ALL cell lines have lost this trait. This may be particularly relevant for
NOTCH1-independent T-ALL cell lines where only few examples exist and have been extensively
cultured in vitro. As part of our efforts to develop better tools for understanding the role of MYC
activation and PTEN loss-of-function in NOTCH1-independent T-ALL, we established a new cell
line named University of Padua T-cell acute lymphoblastic leukemia 13 (UP-ALL13) harboring
t(8:14)(q24;q11) with co-occurring abnormalities including deletions/alterations in CDKN2A/B,
SIL-TAL1, PTEN, and LMO2. In addition, sequencing of UP-ALL13 revealed additional mutations in a
limited number of genes, including a heterozygous R882H mutation affecting DNA methyltransferase
enzyme 3A (DNMT3A) that is typically found in myeloid leukemia [17]. In this cell line, we also
describe genes associated with putative super-enhancers (defined by exceedingly high levels of histone
H3 lysine 27 acetylation (H3K27ac)). Finally, we evaluated the sensitivity of UP-ALL13 to therapeutic
agents either currently used for the treatment of T-ALL or novel targeted therapies which could be
effective in this model of NOTCH1-independent leukemia.
2. Materials and Methods
Patient material: Primary leukemia cells were obtained from the peripheral blood (PB) of a
5-year-old male patient at diagnosis. Informed consent and approval by the Azienda Ospedaliera di
Padova Review Board were obtained according to general guidelines, conforming with the Declaration
of Helsinki.
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Establishment and in vitro maintenance of the UP-ALL13 cell line: Procedures involving animals
and their care conformed with institutional guidelines that comply with national and international
laws and policies (European Economic Community (EEC) Council Directive 86/609, OJ L 358,
12 December 1987) and were authorized by the local ethical committee on animal welfare. Primary
T-ALL cells (10 × 106) from PB were injected in vivo via intravenous injection (IV) into 6–8 week old
female Nonobese diabetic/severe combined immunodeficiency interleukin 2 receptor gamma chain
null (NOD SCID IL2Rγnull) (NSG) immunodeficient mice. Mice were euthanized upon development
of signs of leukemia, at which point PB, spleen, and bone marrow (BM) were collected and analyzed
for the presence of human leukemic cells (as judged by cluster of differentiation 45 (CD45) and/or CD7
expression). Authenticated human leukemia cells isolated from the spleen were then re-passaged in the
mice. After approximately five passages in the mice, in vitro culturing of leukemia cells was attempted
by seeding cells in 24-well plates at 2 and 4 × 106/mL in Minimum Essential Medium (MEM-alpha)
supplemented with 10% fetal bovine serum (FBS), 10% human heat-inactivated AB serum, antibiotics,
ultra-glutamine, and 10 ng/ml recombinant Interleukin-7 (IL-7) (PeproTech, London, United Kingdom).
This strategy was used for the initial month of in vitro culture; subsequently, leukemic cells were
cultured in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 20% FBS
(RPMI–20%FBS) at a density of 2 × 106/mL. Medium was changed periodically, and cells were
passaged every 5–6 days. UP-ALL13 cells were maintained in continuous culture in RPMI–20% FBS
for more than 9 months.
Immunophenotype: Primary leukemia cells were phenotyped at the moment of diagnosis by using
standard protocols [18]. Flow cytometric analysis of freshly isolated xenograft cells (passage ≈ 10)
and UP-ALL13 cells (≈8 months of in vitro culture) was performed using fluorochrome-conjugated
monoclonal antibodies (mAbs) (Table 1) obtained from BD Pharmingen (San Diego, CA, USA)
and Beckman-Coulter (Miami, FL, USA). Samples were analyzed using the BD FACSCanto™ II
(Beckman-Dickinson, Roswell Park Memorial Institute, NY, USA) flow cytometer.
Clonality assessment, DNA fingerprinting, and cytogenetic and fluorescence in situ hybridization
analysis: T-cell receptor (TCR) gene rearrangements were analyzed in the primary leukemia cells at
diagnosis and in cells obtained from the xenograft in order to check if clonality was maintained after
passage into NSG mice. Genomic DNA was isolated from primary leukemia cells at diagnosis and
xenograft cells, and PCR analysis was performed to detect TCRD, TCRG, and TCRB rearrangements
using methods and primers previously described [19,20]. Clonal gene rearrangements, identified
by homo/heteroduplex analysis, were sequenced by a dye-terminator cycle sequencing kit on an
ABI Prism 310 apparatus (Life Technologies, Carlsbad, CA, USA) [21]. The genetic identity of the
derived cell line with respect to the original primary leukemia cells from the patient was confirmed by
analyzing several loci of short tandem repeats (STRs) using a commercial kit (PowerPlex 16 HS System,
Madison, WI, USA). Metaphase chromosome preparations were obtained from the UP-ALL13 cell line
after overnight exposure to 100 ng/mL colcemid (KaryoMAX Colcemid solution, Life Technologies,
Carlsbad, CA, USA). G-banding was performed with Wright Stain (Sigma Aldrich, St. Louis, MO,
USA) and the karyotype was described following International System for Human Cytogenetic
Nomenclature (ISCN) 2016 nomenclature, after the analysis of 25 metaphases with IKAROS software
(Metasystems, Altlussheim, Germany). Fluorescence in situ hybridization (FISH) was performed by
standard method with a break-apart probe for MYC (Zytolight SPEC MYC dual break-apart probe,
ZytoVision, Bremerhaven, Germany). Hybridization signals were scored on at least 10 metaphases
and 100 interphase nuclei using ISIS software (Metasystems) and an AxioImager Z2 microscope (Zeiss,
Jena, Germany) equipped with appropriate filters.
Proliferation, apoptosis, and cell cycle analysis after treatment with signaling-specific inhibitors
and chemotherapeutic drugs: T-ALL cell lines were purchased from the Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ) repository (Braunschweig, Germany) and cultured at
37 ◦C (5% CO2) in RPMI–10% FBS. All cell lines were periodically authenticated by STR profiling
and tested for Mycoplasma contamination. We analyzed cell viability in UP-ALL13, NOTCH1 mutant
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T-ALL cell lines (DND41, CUTLL1) and established t(8;14)(q24:q11)-translocated T-ALL cell lines
(MOLT-16, SKW-3/KE-37) via the bioluminescent method Vialight plus (Lonza, Basel, Switzerland)
after the indicated time points. In detail, duplicate cultures of UP-ALL13 cells (5 × 105) or T-ALL
cell lines (3 × 105) were seeded in 24-well flat-bottomed plates and treated with increasing doses of
various compounds: EPZ5676, AZD5153, JQ1, and EPZ004777 (Selleck Chemicals LLC, Houston, TX,
USA), etoposide and dexamethasone (Sigma-Aldrich), and dibenzazepine (DBZ; Syncom, Groningen,
the Netherlands). All drug experiments were repeated at least twice, with similar results. We analyzed
apoptosis by flow cytometry (FACS) after staining with Annexin V- Fluorescein-5-Isothiocyanate
(FITC) (Roche, Burgess Hill, UK) and SYTOX Red dead cell stain (Invitrogen, Paisley, UK).
Cell cycle distribution was performed by assessing DNA content using propidium iodide (PI; Sigma).
The samples were collected on a FACSCalibur (BD Biosciences, Milan, Italy) using Cell Quest software
(BD Biosciences) and analyzed with FlowJo (FLOWJO LLC, Ashland, OR, USA).
Table 1. Immunophenotype of parental leukemia T-cells, xenograft cells, and the UP-ALL13 cell line.
Marker Primary Leukemia Cells Xenograft UP-ALL 13 Cell Line
CD1a Neg. Pos (D) Neg.
CD2 Pos (B) Pos (B) Pos (B)
sCD3 Pos (D) Pos (M) Pos (M)
CyCD3 Pos (B) Pos (B) Pos (B)
CD4 Pos (D) PP2 Pos (D)
CD8 Pos (D) PP2 Pos (H)
CD5 Pos (B) Pos (B) Pos (B)
CD7 Pos (B) Pos (H) Pos (B)
TCRαβ Neg. Pos (D) Pos (M)
TCRγδ Neg. Neg. Neg.
CD19 Neg. Neg. Neg.
HLA-DR Neg. Neg. Neg.
CD16 Neg. Neg. Neg.
CD56 Neg. Neg. Neg.
CD11a Pos (B) Pos (B) Pos (B)
CD11b nd Neg. Neg.
CD11c nd Neg. Neg.
CD13 Neg. Pos (D) Pos (D)
CD14 Neg. Neg. Neg.
CD15 nd PP2 Pos (H)
CD33 Neg. Neg. Neg.
CD34 Neg. Pos (D) Pos (D)
CD38 nd Pos (B) Pos (B)
CD44 Pos (B) Pos (B) Pos (B)
CD99 Pos (B) Pos (B) Pos (B)
Definition of the antigen expression rating is based on the Associazione Italiana Emato-Oncologia
Pediatrica-Berlin-Frankfurt-Munster (AIEOP-BMF) consensus guidelines [18]: Pos = positive, Neg = negative,
(B) = bright, (M) = medium, (D) = dim, (H) = heterogeneous, PP1 = partially positive 1, PP2 = partially positive 2;
nd = not determined; s = surface; Cy = cytoplasmic.
Array comparative genomic hybridization (aCGH): Copy number alterations were profiled in
cells obtained from the patient xenograft and UP-ALL13 cell line using the 180K custom-designed
oligonucleotide array platform (Agilent SurePrint G3 Human CGH microarrays, G4449A, design ID:
022060). Genomic DNA from samples and standard controls was labeled using random prime labeling
with Cy3 and Cy5 dyes (Perkin Elmer, Waltham, MA, USA). Hybridization was performed according
to the manufacturer’s instructions (Agilent Technologies, Santa Clara, CA, USA). Data were analyzed
using the Comprehensive Platform for the analysis and visualization of Structural Genomic Variation
(ViVar) software [22] arrayCGHbase tool.
Whole exome sequencing and mutational analysis: Whole exome sequencing (WES) was
performed using DNA extracted from PB patient mononuclear cell pellets which was subjected
to Sure Select capture technology (Human All Exome V6 Kit, Agilent) and paired-end sequencing
on an Hiseq3000 device (Illumina Inc., San Diego, CA, USA). Alignment with the reference genome
was performed using a Burrows–Wheeler Aligner (BWA) and somatic variant calling was executed by
MuTect [23] and Strelka [24].
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Mutations detected by WES of the genes: ABCA4, DNMT3A, FADS6, FGFR3, GNB2, GPR39, IFIT1B,
LRRC74A, NBPF10, PCDHB6, PMM1, SCRIB, SPATA31D3, VCX, and LCE1E were independently
amplified and subjected to Sanger sequencing. Mutational analysis was performed on two independent
PCR products containing the putative mutation found by WES and evaluated using DNAdynamo
tool. Primers of sequenced genes with allelic frequency (AF) > 0.22 are listed in the supplement
(Supplementary Table S1).
Immunoblot analysis: Total cell lysates were prepared using RadioImmunoprecipitation Assay
(RIPA) lysis buffer supplemented with phosphatase inhibitor cocktail set I and II (Sigma) and
protease inhibitor cocktail tablets (Roche) and normalized for protein concentration using the
Bicinchoninic Acid (BCA) method (Pierce, Pero, Italy). For Western blotting, protein samples were
separated on 4–12% gradient Tris–glycine SDS-PAGE (Invitrogen) and transferred to PVDF membrane
(Millipore, Burlington, MA, USA). Antibodies against Protein Tyrosine Phosphatase Receptor Type C
(PTPRC/CD45) (H-230, sc-25590), c-myc (9E10, sc-40), and p53 (DO-1, sc-126) were from Santa Cruz
Biotechnology (Dallas, Texas, USA); antibodies recognizing CXCR4 (ab124824) and MYB (ab117635)
were from Abcam (Cambridge, UK); and antibodies recognizing LEF1 (C12A5, #2230), cleaved caspase
3 (#9661), and β-actin (D6A8, #8457) were from Cell Signaling Technologies (Danvers, MA, USA).
H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq): UP-ALL13 cells (2 × 107) were
cross-linked with methanol-free formaldehyde (1% final concentration) at room temperature for 7 min
and the cross-linking reaction was quenched with glycine (125 mM final concentration, Sigma-Aldrich).
Nuclei were isolated and chromatin was purified by chemical lysis (truChIP Chromatin Shearing
Reagent KIT, Covaris, Woburn, MA, USA) and processed as previously described [8].
Statistical analysis: We performed statistical analysis by Student’s t-test and Mann-Whitney U
test where appropriate. All statistical tests were two-sided, and p < 0.05 was considered statistically
significant. Results are shown as mean of quadruplicate wells. Error bars represent ± standard
deviation. Survival in animal experiments was represented with Kaplan–Meier curves (GraphPad
Prism Software, San Diego, CA, USA).
3. Results
3.1. Establishment of a New NOTCH1-Independent T-ALL Cell Line that Engrafts in Immune-Deficient Mice
The considerable rate of spontaneous apoptosis and lack of significant spontaneous in vitro
expansion of leukemic T cells prompted us to use a different strategy to establish novel
NOTCH1-independent T-ALL cell lines. In fact, to circumvent the obstacles encountered
following in vitro culture, we established a new cell line through serial passages in the permissive
microenvironment of NSG mice. Lymphoblast cells from the PB of a 5-year-old boy at the time
of diagnosis were injected into NSG mice. The main clinical features of the leukemia patient are
summarized in supplemental Table S2. In all animals initially injected (n = 3), the leukemic cells
engrafted with leukemia, infiltrating numerous organs including the bone marrow and spleen with
a time to leukemia of approximately 35 days. No evidence of thymus enlargement or mediastinal
mass was observed. Leukemic cells were recovered from the spleen of diseased animals and injected
into secondary recipient animals. Prior to each in vivo passage, authenticity of the leukemic cells
with respect to the original patient material was evaluated through TCR rearrangement and DNA
microsatellite fingerprints (STR). After the fifth in vivo passage, in vitro culturing of leukemic cells
from diseased animals was attempted. After numerous attempts, a cell line was obtained that grew
continuously in culture. This cell line was named UP-ALL13 and was in continuous culture for over
9 months. UP-ALL13 cells show a doubling time of 60–72 h and can be frozen and thawed successfully.
Microsatellite fingerprinting results from UP-ALL13 and primary leukemia cells used to establish this
cell line demonstrated that they share a unique DNA fingerprint. TCR rearrangements and STR results
for the UP-ALL13 cell line, xenograft, and primary sample are provided in the supplemental material
(Table S3).
Cells 2018, 7, 160 6 of 17
Animal models to study molecular mechanisms as well as drug efficacy of NOTCH1-independent
T-ALL in vivo are desirable to further enhance mechanistic studies. To determine tumorigenicity,
UP-ALL13 cells were transplanted IV into NSG mice (5–10 × 106 viable cells/mouse). In all animals
tested (n = 3), UP-ALL13 cells engrafted and determined leukemia disseminating to multiple organs.
Animals developed disease and were euthanized at 37.7± 9 days after cell injection (range, 32–48 days;
Figure 1a). Histological analysis disclosed the involvement of BM and lymphoid organs such as the
spleen and liver in all animals (Figure 1b). Involvement of kidneys was also noted (not shown), with no
evidence of thymus enlargement or mediastinal mass. Importantly, recovered leukemic cells from
diseased mice maintained the capacity to grow when cultured in vitro and maintained their genetic
identity (data not shown).Cells 2018, 7, x FOR PEER REVIEW  6 of 17 
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3.2. UP-ALL13 Is a New T-ALL Cell Line with t(8;14)-Translocation Involving the MYC Proto-Oncogene and
Presenting a Heterozygous R882H DNMT3A Mutation
To evaluate whether UP-ALL13 share the patient’s primary leukemia cell phenotype,
immunophenotypic and clonality analyses were executed in uncultured primary leukemia cells,
xenograft cells, and UP-ALL13 cells cultured in vitro. Immunophenotypic analysis of the UP-ALL13
cell line and primary sample disclosed an overlapping phenotype with expression of CD7, CD2,
CD5, and surface CD3 (sCD3), and lack of CD1a, B-cell (CD19), or natural killer (CD16/CD56) cell
surface markers (Table 1). Interestingly, some myelomonocytic lineage markers (CD13 and possibly
CD15) were partially expressed in the UP-ALL13 cell line compared to the parental cells. Altogether,
this pattern of expression is consistent with a mature thymocyte phenotype of both primary sample
and derived T-ALL cell line.
Cytogenetic analysis of the UP-ALL13 cell line showed a diploid male karyotype of
46 chromosomes with a single chromosomal translocation t(8;14)(q24;q11): 46, XY, t(8;14)(q24;q11)
(Figure 2a). This recurrent chromosomal translocation typically involves the MYC proto-oncogene
(mapping on 8q24) and the TCRA/D locus in chromosome 14q11, and it is found in approximately
1–6% of adult and pediatric T-ALL cases [7]. The involvement of the MYC proto-oncogene was
further confirmed by FISH on metaphases with a break-apart probe for MYC (Figure 2b). Targeted
locus amplification (TLA) [25] further corroborated the above results (data not shown). aCGH on
the primograft (not shown) and the established UP-ALL13 cell line (Figure 2c), confirmed the TCR
A/D deletion and revealed a limited number of additional alterations including bi-allelic deletions of
CDKN2A/B and mono-allelic deletions of PTEN together with STIL/TAL1 and LMO2 alterations. On the
other hand, no mutations were found by targeted Sanger sequencing in other genes commonly altered
in T-ALL, such as FBXW7, PHF6, WT1, and most notably NOTCH1 (data not shown). In agreement
with NOTCH1 sequencing data, treatment with a gamma secretase inhibitor (dibenzazepine; DBZ)
for a prolonged period of time (6–7 days) did not significantly impact on proliferation and did not
induce cell cycle arrest (Supplementary Figure S1), suggesting independence from NOTCH1 signaling
for leukemia maintenance. Thus, the genetic profile of our leukemia cell line with t(8;14)(q24;q11)
translocation and NOTCH1wt/FBXW7wt/PTEN deletion is compatible with a recently identified
NOTCH1-independent/MYC-mediated T-ALL subset [12].
To further investigate the genetic profile of our NOTCH1-independent T-ALL, we performed
WES of the parental diagnosis (and remission) DNA sample. This analysis allowed us to detect
mutations in additional genes (ABCA4, DNMT3A, FADS6, FGFR3, GNB2, GPR39, IFIT1B, LRRC74A,
NBPF10, PCDHB6, PMM1, SCRIB, SPATA31D3, VCX, and LCE1E). Of these genes, we were able to
validate by Sanger sequencing mutations affecting DNMT3A, LRRC74A, PCDHB6, PMM1, ABCA4,
and SPATA31D3 which had an AF > 0.22 (Figure 3a and Supplementary Figure S2). All these additional
mutations were replicated in the DNA obtained from primo-xenograft and the UP-ALL13 cell line,
further demonstrating their clonal derivation from the patients’ leukemic cells. Particularly interesting
was the finding of the heterozygous R882H mutation affecting DNMT3A, which is a mutational
hotspot in acute myeloid leukemia (AML) and early T-cell precursor (ETP) adult T-ALL, but is rarely
encountered in pediatric T-ALL [26].
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and LMO2 loci.
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percentage of the Dimethyl Sulfoxide (DMSO) control cells at each time point. Error bars represent ± 
standard deviation of quadruplicate wells. (c) Cell viability of UP-ALL13, CUTLL1, and DND41 cells 
treated for 3 and 7 days with a dose of 20 μM of EPZ5676. Viability is shown as a percentage of the 
DMSO control cells at each time point. Error bars represent ± standard deviation of quadruplicate 
wells. *, p < 0.05. 
Recently, murine hematopoietic stem cells (HSCs) in which Dnmt3a had been conditionally 
deleted were shown to overexpress the histone 3 lysine 79 (H3K79) methyltransferase Dot1l, leading 
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Recently, murine hematopoietic stem cells (HSCs) in which Dnmt3a had been conditionally
deleted were shown to overexpress the histone 3 lysine 79 (H3K79) methyltransferase Dot1l, leading
to increased H3K79 DNA methylation [27]. Pharmacological inhibition of DOT1L by EPZ5676 or
EPZ004777 leads to a significant anti-leukemic effect in vitro and in vivo in DNMT3A-mutant AML
primary samples and cell lines [27]. Since our T-ALL cell line (UP-ALL13) also harbors a R882
DNMT3A mutant, we evaluated in vitro the therapeutic efficacy of DOT1L inhibition by EPZ5676 [28].
We found only a modest dose- and time-dependent reduction in cell viability (Figure 3b). Indeed,
only prolonged exposure to high doses of EPZ5676 (20 µM) for 7 days significantly impacted cell
survival, as compared to two T-ALL cell lines (CUTLL1, DND41) not known to harbor DNMT3A
mutants (Figure 3c). A similar effect was seen using another DOT1L inhibitor such as EPZ004777
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(data not shown). This finding may be due to the different mechanism of action of the DNMT3A
mutation in T-ALL compared to AML [27].
3.3. A Super-Enhancer Portrait in the NOTCH1-Independent T-ALL Cell Line UP-ALL13
Not much is known regarding the enhancer elements which are important for
maintaining NOTCH1-independent T-ALL. In order to identify active enhancers, promoters,
and super-enhancers [29], we performed chromatin immunoprecipitation coupled to high-throughput
sequencing (ChIP-seq) with an antibody against the enhancer-associated histone modification H3K27ac
on UP-ALL13 cells. We found numerous regions with high levels of H3K27ac, with exceptionally
high levels of H3K27ac in a relatively small set of large enhancer regions (possibly super-enhancers).
Enhancers tend to loop to and associate with adjacent genes in order to activate transcription [30–32].
Most of these interactions occur within a distance of ≈50 kb of the enhancer [33]. Using a simple
proximity rule, we assigned transcriptionally active genes to super-enhancers within a 50-kb
window [34]. This procedure allowed us to identify numerous genes associated with super-enhancers,
including various genes implicated in T-ALL and cancer pathogenesis in general, such as PTPRC
(CD45), IKZF1 (Ikaros), CXCR4, ELF-1, IKZF2 (Helios), WNT8B, CCND3, RUNX1, HDAC1 and 7,
SOCS1, CIITA, TCF12, LEF1, MYB, BCL2, and MYC (Figure 4). The identification of key oncogene
drivers regulated by super-enhancers in UP-ALL13 could help in determining the oncogenic drivers
behind NOTCH1-independent T-ALL, which could cause a predisposition to disproportionate
sensitivity to loss of bromodomain and extraterminal (BET) chromatin reader proteins such as the
bromodomain-containing protein 4 (BRD4) cofactor.
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sequencing identifies putative super-enhancers in UP-ALL13 cells. Hockey-stick plot representing
the normalized rank and signal of H3K27ac peaks in t(8;14)(q24;q11)-positive UP-ALL13 cells.
Representative super-enhancer-associated genes are shown in red.
3.4. UP-ALL13 Is Highly Sensitive to the Bromodomain-Containing Protein 4 (BRD4) Inhibitor AZD5153
and Glucocorticoids
Cell lines are often utilized to screen therapeutic agents relevant to the therapy of the respective
malignancy. Given the peculiar genetic properties of our newly established cell line, we evaluated
the effectiveness of several different therapeutic agents which could be effective in this model
of NOTCH1-independent leukemia. BET chromatin reader proteins, particularly BRD4, play a
critical role in many hematological and solid tumors, by acting as coactivators for the expression
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of proliferative genes. Particularly, BRD4 is required for the expression of MYC, an oncogenic
driver in many cancers [35,36]. The genes particularly sensitive to BET inhibition are typically
associated with large clusters of enhancers highly enriched with the initiation cofactor Mediator,
BRD4, and H3K27Ac, and have been termed as super-enhancers (initially known as locus control
regions) [29,37]. Super-enhancers, like enhancers, often upregulate gene expression through long-range
interactions with the promoters of those genes [38]. This observation has attracted considerable
attention, as therapeutic inhibition of BRD4–histone interactions represent a novel strategy to target
MYC-dependent cancers. Since deregulated expression of MYC through TCRA/D-MYC translocation
(and also possibly through PTEN loss [12]) is a trait of this cell line, and in a recently identified
NOTCH1-independent/MYC-mediated T-ALL subset [12] we evaluated the efficacy of a new,
potent and selective BET/BRD4 bromodomain inhibitor, AZD5153 [39]. This compound, in contrast
to JQ1, is a bivalent BET bromodomain inhibitor [39]. As shown in Figure 5a, UP-ALL13 was very
sensitive (half maximal inhibitory concentration, IC50 < 100 nM at 24 h) to the BET/BRD4 bromodomain
inhibitor AZD5153, as compared to other common T-ALL cell lines harboring NOTCH1-activating
mutations (DND41) or the rare t(7;9) translocation, leading to a constitutively active truncated
membrane-bound form of NOTCH1 (CUTLL1; not shown). Surprisingly, other MYC-rearranged
T-ALL cell lines (MOLT-16, SKW-3/KE-37), while reported to be relatively sensitive to the BET/BRD4
inhibitor JQ1 [8] (and Figure S3), resulted much more resistant to AZD5153 compared to UP-ALL13 at
24 h, much like the non-MYC translocated cell line DND41. On the other hand, UP-ALL13 was also
highly sensitive to JQ1 (Figure S3). The loss of viability following AZD5153 exposure of UP-ALL13
was mainly due to marked induction of apoptosis (Figure 5b) and not due to cell cycle arrest (data not
shown). Western blot analysis of UP-ALL13 cells treated with different doses of AZD5153 demonstrated
a dose-dependent decrease in oncogenic drivers putatively under the control of super-enhancers such
as MYC, MYB, and β-catenin, which was associated with marked induction of cleaved caspase 3
(Figure 5c,d). Interestingly, other non-transcription factor molecules (PTPRC/CD45 and CXCR4)
putatively under the control of super-enhancers showed a less pronounced dose-dependent decrease
following exposure to AZD5153 (Figure 5c,d).
In addition to AZD5153, we also evaluated the sensitivity of UP-ALL13 to glucocorticoids
(dexamethasone) and etoposide. We found the UP-ALL13 cell line to be exquisitely sensitive to
dexamethasone (IC50 ≈10 nM at 48 h), especially compared to other common T-ALL cell lines
(Figure 5e) such as DND41 (IC50 ≈200 nM; glucocorticoid-sensitive) and CUTLL1 (IC50 >10 µM;
glucocorticoid-resistant).
Sequence analysis of the TP53 gene in UP-ALL13 did not show the presence of any mutation
within its coding region (data not shown), and coherently the UP-ALL13 cell line was found to be
highly sensitive to the DNA-damaging agent etoposide, in contrast to p53 mutant T-ALL cell lines such
as DND41 and CUTLL1 (Figure 5f). Western blot analysis demonstrated considerable p53 stabilization
following etoposide treatment, further corroborating a functional p53 response (Figure 5g) in this
cell line, in contrast to the p53 mutant CUTLL1 cell line where p53 stabilization was already present
under basal conditions. Overall, these studies demonstrate that UP-ALL13 is a useful tool for testing
therapeutic agents targeting signaling pathways de-regulated in T-ALL.
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4. Discussion
Translocation t(8;14)(q24;q11), initially described in pediatric patients and detected in
≈ 1–6% of T-ALL cases, has been associated with an aggressive disease characterized by
hyperleukocytosis, lymphoma-like presentation, rapid neurological progression, and poor response to
chemotherapy [7,40]. The main clinical characteristics of the patient from whom the
NOTCH1-independent cell line UP-ALL13 was derived fits this description (Table S2). These T-ALLs
cluster with TAL1/LMO2-rearranged mature leukemias based on their gene expression
signature [7,8]. In t(8;14)(q24;q11), the MYC proto-oncogene is over-expressed through its juxtaposition
to the TCR A/D locus. The genetic profile of these t(8;14)(q24;q11)-translocated T-ALLs is often
characterized by NOTCH1wt/FBXW7wt/PTEN mutation or deletion and agrees with that of putative
leukemia-initiating cells described in a Pten-null mouse T-ALL model.
The UP-ALL13 cell line shares the genetic and immuno-phenotypic characteristics of the parental
leukemia cells, including a lack of NOTCH1 and TP53 mutations, while maintaining the heterozygous
DNMT3A R882H mutation. The mutational spectrum of DNMT3A seems to be different in (adult)
T-ALL cases compared to myeloid malignancies such as AML. Although almost all DNMT3A
mutations in AML are heterozygous, T-ALL patients frequently harbor homozygous [41] or compound
heterozygous DNMT3A mutations [42]. Additionally, the distribution of the mutations in DNMT3A
is more diverse in T-ALL, with the prevalence of mutations affecting the R882 “hot spot” accounting
for less than 20%, compared to over 40% in AML [41,43]. Recent studies indicate that the R882
mutant results in a hypomorphic protein [44] that acts as a dominant negative variant, restraining
the methyltransferase activity of the remaining wild-type DNMT3A protein. This heterozygous
mutation at R882 reduces the methyltransferase activity to approximately 20% of that of the wild-type
protein [45,46]. On the other hand, other heterozygous DNMT3A mutations (non-R882) can only lower
the methyltransferase activity to about 50% of the wild-type protein, suggesting that these mutations
may not be sufficient to drive malignancy on their own but select for a second mutation (or loss of
heterozygosity) [43]. The prognostic importance of the DNMT3A mutations is debated, but on the
whole they have no impact on outcome, at least in primary AML [41,43]. In T-ALL, patients with
DNMT3A mutations have been reported to have a significantly poorer overall survival compared to
patients with wild-type DNMT3A [41], but it is not clear whether this finding is just a consequence of
the fact that DNMT3A mutations are enriched in the more immature T-ALL subtypes, which show a
poorer prognosis compared to mature T-ALL [26,42,47]. Interestingly, notwithstanding the presence of
the R882 DNMT3A mutant in UP-ALL13, we found little evidence of therapeutic efficacy of DOT1L
inhibition. This finding suggests that the mechanism of action of DNMT3A mutations in T-ALL may
be different to AML, possibly due to the necessity of contributing genetic or epigenetic aberrations in
T-ALL compared to AML [27].
Another interesting finding was that BRD4 inhibition using AZD5153 resulted particularly
effective in contrasting viability and proliferation of UP-ALL13 cells. This supports the idea that
this cell line is “addicted” to oncogenes reliant on super-enhancers for high-level expression such
as MYC. Particularly intriguing were the results of the H3K27ac ChIP-seq, useful for identifying
putative super-enhancers. In fact, putative super-enhancers were associated with transcription factors
implicated in: (1) lymphocyte development, including T-lineage specification and maturation (IKZF1,
IKZF2, ETS1); (2) T-ALL transcription factor oncogenes (MYB, MYC); (3) Wnt/ß-catenin signaling
(LEF1); (4) cell cycle regulators (CCND3); (5) invasion/metastasis genes (CXCR4); and (6) anti-apoptotic
members of the Bcl-2 family (BCL2). Interestingly, we found super-enhancers near not only oncogenes
but also tumor suppressor genes (IKZF1, LEF1, RUNX1), implying that not all super-enhancer
associated genes contribute to tumor progression. Recently, other groups have also reported tumor
suppressor gene association with super-enhancers [48,49]. Thus, in some instances the preferential
targeting of super-enhancer associated tumor suppressor genes may lead to tumor progression rather
than regression.
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Altogether, our collective results seem to suggest that certain types of NOTCH1-independent
human T-ALL have de-regulated expression of MYC, PTEN inactivation, and possibly β-catenin
activation, as recently reported for some Pten-deleted mouse models of T-ALL [11,50]. Very recently,
H3K27ac ChIP-seq was performed in MOLT-16 cells harboring the t(8;14)(q24;q11) translocation [8].
In this cell line, the highest levels of H3K27ac were found in the enhancer elements of the TCRA/TCRD
locus known to drive MYC expression. Consistently, in this study MOLT-16 cells resulted particularly
sensitive to the BRD4 inhibitor JQ1 [8] (known to target MYC). We found UP-ALL13 also to be highly
sensitive to JQ1 (Figure S3), confirming the therapeutic efficacy of BET bromodomain inhibition in
this leukemia model. On the other hand, we found MOLT-16 cells to be more resistant to the bivalent
BET bromodomain inhibitor AZD5153, especially at early time points (24 h). This molecule has been
found to target a more varied transcriptional/signaling program compared to JQ1 including MYC, E2F,
and mTOR [39], suggesting that MOLT-16 cells may not be so reliant on these additional pathways for
their proliferation. Altogether our findings suggest that UP-ALL13 cells may represent a more faithful
model of transcriptionally addicted cancer cells and could be useful to gain mechanistic insights on
the action of BRD4 inhibitors.
In conclusion, we describe a cell line, UP-ALL13, derived from a patient with T-ALL that
was NOTCH1-independent and harbored the t(8;14)(q24;q11) translocation, leading to de-regulated
expression of MYC. This cell line may be useful as a model system for dissecting the signaling pathways
implicated in T-ALL survival and growth independent from NOTCH1 and for the screening of targeted
anti-leukemia agents specific for this T-ALL subgroup.
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